Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology
- 21 March 2014
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 6 (7-8) , 728-738
Abstract
Deterrence of synthetic cathinone abuse is hampered by the lack of a high‐throughput immunoassay screen. The Randox Drugs of Abuse V (DOA‐V) Biochip Array Technology contains two synthetic cathinone antibodies: Bath Salt I (BSI) targets mephedrone/methcathinone and Bath Salt II (BSII) targets 3’,4’‐methylenedioxypyrovalerone (MDPV)/3’,4’‐methylenedioxy‐α‐pyrrolidinobutiophenone (MDPBP). We evaluated DOA‐V synthetic cathinones performance and conducted a full validation on the original assay with calibrators reconstituted in water, and the new assay with calibrators prepared in lyophilized urine; both utilized the same antibodies and were run on the fully automated Evidence® Analyzer. We screened 20 017 authentic military urine specimens and confirmed positives by liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) for 28 synthetic cathinones. Limits of detection (LOD) for the original and new assays were 0.35 and 0.18 (BSI), and 8.5 and 9.2 µg/L (BSII), respectively. Linearity was acceptable (R2 > 0.98); however, a large negative bias was observed with in‐house prepared calibrators. Intra‐assay imprecision was <20% BSI‐II, while inter‐assay imprecision was 18‐42% BSI and <22% BSII. Precision was acceptable for Randox controls. Cross‐reactivities of many additional synthetic cathinones were determined. Authentic drug‐free negative urine pH <4 produced false positive results for BSI (6.3 µg/L) and BSII (473 µg/L). Oxidizing agents reduced BSI and increased BSII results. Sensitivity, specificity, and efficiency of 100%, 52.1%, and 53.0% were obtained at manufacturer's proposed cut‐offs (BSI 5 µg/L, BSII 30 µg/L). Performance improved if cut‐off concentrations increased (BSI 7.5 µg/L, BSII 40 µg/L); however, there were limited confirmed positive specimens. Currently, this is the first and only fully validated immunoassay for preliminary detection of synthetic cathinones in urine. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.Keywords
Funding Information
- National Institute on Drug Abuse
- Department of Defense Counter Narcotics Program
This publication has 54 references indexed in Scilit:
- Investigating the ‘bath salt’ panic: The rarity of synthetic cathinone use among students in the United StatesDrug and Alcohol Review, 2013
- The Stability of Four Designer Drugs: MDPV, Mephedrone, BZP and TFMPP in Three Biological Matrices under Various Storage ConditionsJournal of Analytical Toxicology, 2013
- Screening of Stimulants Including Designer Drugs in Urine Using a Liquid Chromatography Tandem Mass Spectrometry SystemJournal of Analytical Toxicology, 2013
- “Legal highs”—Toxicity in the clinical and medico-legal aspect as exemplified by suicide with bk-MBDB administrationForensic Science International, 2012
- Intoxication Delirium following Use of Synthetic Cathinone DerivativesThe American Journal of Drug and Alcohol Abuse, 2012
- Evidence of mephedrone chronic abuse through hair analysis using GC/MSForensic Science International, 2012
- Determination of the amphetamine-like designer drugs methcathinone and 4-methylmethcathinone in urine by LC-MS/MSAnnales de Toxicologie Analytique, 2011
- Drugs for youth via Internet and the example of mephedroneToxicology Letters, 2011
- Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatography–electrospray tandem mass spectrometryJournal of Chromatography B, 2011
- Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information ServiceEmergency Medicine Journal, 2010